Early triple antiviral therapy for COVID-19

Nelson Lee; Michael Ison; Jake Dunning

doi:10.1016/S0140-6736(20)32274-1

Early triple antiviral therapy for COVID-19

Nelson Lee, Michael Ison, Jake Dunning

Research output: Contribution to journal › Letter › peer-review

Original language	English (US)
Pages (from-to)	1487-1488
Number of pages	2
Journal	The Lancet
Volume	396
Issue number	10261
DOIs	https://doi.org/10.1016/S0140-6736(20)32274-1
State	Published - Nov 7 2020

Funding

NL reports non-financial support from Shionogi; personal fees and non-financial support from Janssen Pharmaceuticals, Roche, and Sanofi Pasteur; personal fees and other support from Gilead Sciences and Genetech; and personal fees from Cidara Therapeutics, outside the submitted work. MI reports grants from AiCuris and Shire; grants, personal fees, and other support from Janssen; personal fees and other support from Allovir; personal fees from Celltrion, Roche, Shionogi, Viracor Eurofins; and other support from Merck, Sequiris, Takeda, Vitaeris, SAB Biotherapeutics, outside the submitted work. JD declares no competing interests.

ASJC Scopus subject areas

General Medicine

Access to Document

10.1016/S0140-6736(20)32274-1

Cite this

@article{88158cef54b9471ea3fe40402109812b,

title = "Early triple antiviral therapy for COVID-19",

author = "Nelson Lee and Michael Ison and Jake Dunning",

note = "Funding Information: NL reports non-financial support from Shionogi; personal fees and non-financial support from Janssen Pharmaceuticals, Roche, and Sanofi Pasteur; personal fees and other support from Gilead Sciences and Genetech; and personal fees from Cidara Therapeutics, outside the submitted work. MI reports grants from AiCuris and Shire; grants, personal fees, and other support from Janssen; personal fees and other support from Allovir; personal fees from Celltrion, Roche, Shionogi, Viracor Eurofins; and other support from Merck, Sequiris, Takeda, Vitaeris, SAB Biotherapeutics, outside the submitted work. JD declares no competing interests. ",

year = "2020",

month = nov,

day = "7",

doi = "10.1016/S0140-6736(20)32274-1",

language = "English (US)",

volume = "396",

pages = "1487--1488",

journal = "The Lancet",

issn = "0140-6736",

publisher = "Elsevier B.V.",

number = "10261",

}

TY - JOUR

T1 - Early triple antiviral therapy for COVID-19

AU - Lee, Nelson

AU - Ison, Michael

AU - Dunning, Jake

N1 - Funding Information: NL reports non-financial support from Shionogi; personal fees and non-financial support from Janssen Pharmaceuticals, Roche, and Sanofi Pasteur; personal fees and other support from Gilead Sciences and Genetech; and personal fees from Cidara Therapeutics, outside the submitted work. MI reports grants from AiCuris and Shire; grants, personal fees, and other support from Janssen; personal fees and other support from Allovir; personal fees from Celltrion, Roche, Shionogi, Viracor Eurofins; and other support from Merck, Sequiris, Takeda, Vitaeris, SAB Biotherapeutics, outside the submitted work. JD declares no competing interests.

PY - 2020/11/7

Y1 - 2020/11/7

UR - http://www.scopus.com/inward/record.url?scp=85095457481&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85095457481&partnerID=8YFLogxK

U2 - 10.1016/S0140-6736(20)32274-1

DO - 10.1016/S0140-6736(20)32274-1

M3 - Letter

C2 - 33160566

AN - SCOPUS:85095457481

SN - 0140-6736

VL - 396

SP - 1487

EP - 1488

JO - The Lancet

JF - The Lancet

IS - 10261

ER -

Early triple antiviral therapy for COVID-19

Funding

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this